Comparative Effectiveness of Intravenous Immunoglobulin for Children with Kawasaki Disease: A Nationwide Cohort Study

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Lin, Ming Chih ^a,b,c   Fu, Yun Ching ^a,c   Jan, Sheng Ling ^a,c   Lai, Mei Shu ^b,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ACIDIFICATION; ARTICLE; CHILD; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY ANEURYSM; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRESCHOOL CHILD; RECURRENCE RISK; RETROSPECTIVE STUDY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG FORMULATION; INFANT; KAPLAN MEIER METHOD; RISK; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE;

DISEASE-FREE SURVIVAL; DRUG COMPOUNDING; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; ODDS RATIO; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE;

EID: 84877019238     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063399     Document Type: Article

References (45)

1. Nakamura Y, Yashiro M, Uehara R, Sadakane A, Tsuboi S, et al. (2012) Epidemiologic features of kawasaki disease in Japan: results of the 2009-2010 nationwide survey. J Epidemiol 22: 216-221.
2. Holman RC, Belay ED, Christensen KY, Folkema AM, Steiner CA, et al. (2010) Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J 29: 483-488.
3. Huang WC, Huang LM, Chang IS, Chang LY, Chiang BL, et al. (2009) Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006. Pediatrics 123: e401-405.
4. Park YW, Han JW, Park IS, Kim CH, Cha SH, et al. (2007) Kawasaki disease in Korea, 2003-2005. Pediatr Infect Dis J 26: 821-823.
5. Fischer TK, Holman RC, Yorita KL, Belay ED, Melbye M, et al. (2007) Kawasaki syndrome in Denmark. Pediatr Infect Dis J 26: 411-415.
6. Du ZD, Zhao D, Du J, Zhang YL, Lin Y, et al. (2007) Epidemiologic study on Kawasaki disease in Beijing from 2000 through 2004. Pediatr Infect Dis J 26: 449-451.
7. Heaton P, Wilson N, Nicholson R, Doran J, Parsons A, et al. (2006) Kawasaki disease in New Zealand. J Paediatr Child Health 42: 184-190.
8. Ng YM, Sung RY, So LY, Fong NC, Ho MH, et al. (2005) Kawasaki disease in Hong Kong, 1994 to 2000. Hong Kong Med J 11: 331-335.
9. Lynch M, Holman RC, Mulligan A, Belay ED, Schonberger LB, (2003) Kawasaki syndrome hospitalizations in Ireland, 1996 through 2000. Pediatr Infect Dis J 22: 959-963.
10. Brown TJ, Crawford SE, Cornwall ML, Garcia F, Shulman ST, et al. (2001) CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis 184: 940-943.
11. Gavin PJ, Crawford SE, Shulman ST, Garcia FL, Rowley AH, (2003) Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol 23: 576-581.
12. Nagata S, Yamashiro Y, Maeda M, Ohtsuka Y, Yabuta K, (1993) Immunohistochemical studies on small intestinal mucosa in Kawasaki disease. Pediatr Res 33: 557-563.
13. Naoe S, Takahashi K, Masuda H, Tanaka N, (1991) Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol Jpn 41: 785-797.
14. Rowley AH, Shulman ST, Mask CA, Finn LS, Terai M, et al. (2000) IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J Infect Dis 182: 1183-1191.
15. Suzuki A, Miyagawa-Tomita S, Komatsu K, Nishikawa T, Sakomura Y, et al. (2000) Active remodeling of the coronary arterial lesions in the late phase of Kawasaki disease: immunohistochemical study. Circulation 101: 2935-2941.
16. Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, et al. (1993) Diagnosis and therapy of Kawasaki disease in children. Circulation 87: 1776-1780.
17. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, et al. (1996) Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 94: 1379-1385.
18. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF, (1995) The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 96: 1057-1061.
19. Dajani AS, Taubert KA, Takahashi M, Bierman FZ, Freed MD, et al. (1994) Guidelines for long-term management of patients with Kawasaki disease. Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 89: 916-922.
20. Terai M, Shulman ST, (1997) Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 131: 888-893.
21. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, et al. (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 114: 1708-1733.
22. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, et al. (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315: 341-347.
23. Bonilla F, Geha R (2001) Intravenous Immunoglobulin Therapy. In: Austen KF, editor. Therapeutic immunology. 2nd ed. Malden, Mass.: Blackwell Science. pp. 264-286.
24. Gelfand EW, (2006) Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 6: 592-599.
25. Manlhiot C, Tyrrell PN, Liang L, Atkinson AR, Lau W, et al. (2008) Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Pediatrics 121: e626-630.
26. Manlhiot C, Yeung RS, Chahal N, McCrindle BW, (2010) Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease. Pediatr Allergy Immunol 21: 515-521.
27. Stiehm ER, (2006) Lessons from Kawasaki disease: all brands of IVIG are not equal. J Pediatr 148: 6-8.
28. Tsai MH, Huang YC, Yen MH, Li CC, Chiu CH, et al. (2006) Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin. J Pediatr 148: 38-43.
29. Rosenfeld EA, Shulman ST, Corydon KE, Mason W, Takahashi M, et al. (1995) Comparative safety and efficacy of two immune globulin products in Kawasaki disease. J Pediatr 126: 1000-1003.
30. Lin MC, Lai MS, (2009) Pediatricians' role in caring for preschool children in Taiwan under the national health insurance program. J Formos Med Assoc 108: 849-855.
31. Wen CP, Tsai SP, Chung WS, (2008) A 10-year experience with universal health insurance in Taiwan: measuring changes in health and health disparity. Ann Intern Med 148: 258-267.
32. Leung DY, Cotran RS, Kurt-Jones E, Burns JC, Newburger JW, et al. (1989) Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 2: 1298-1302.
33. Iwata M, Shimozato T, Tokiwa H, Tsubura E, (1987) Antipyretic activity of a human immunoglobulin preparation for intravenous use in an experimental model of fever in rabbits. Infect Immun 55: 547-554.
34. Jungi TW, Santer M, Lerch PG, Barandun S, (1986) Effect of various treatments of gamma-globulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte Fc receptors. A comparative study. Vox Sang 51: 18-26.
35. Nielsen H, (1994) Immunoglobulin preparations for intravenous administration. A review of their biologic activities and comparison of various preparation methods. Allergy 49: 69-73.
36. Aalkjaer C, Cragoe EJ Jr, (1988) Intracellular pH regulation in resting and contracting segments of rat mesenteric resistance vessels. J Physiol 402: 391-410.
37. Austin C, Wray S, (2000) Interactions between Ca(2+) and H(+) and functional consequences in vascular smooth muscle. Circ Res 86: 355-363.
38. Nagesetty R, Paul RJ, (1994) Effects of pHi on isometric force and [Ca2+]i in porcine coronary artery smooth muscle. Circ Res 75: 990-998.
39. Ma XJ, Yu CY, Huang M, Chen SB, Huang MR, et al. (2010) Epidemiologic features of Kawasaki disease in Shanghai from 2003 through 2007. Chin Med J (Engl) 123: 2629-2634.
40. Kuo HC, Yang KD, Chang WC, Ger LP, Hsieh KS, (2012) Kawasaki disease: an update on diagnosis and treatment. Pediatr Neonatol 53: 4-11.
41. Chi H, Huang FY, Chen MR, Chiu NC, Lee HC, et al. (2010) ITPKC gene SNP rs28493229 and Kawasaki disease in Taiwanese children. Hum Mol Genet 19: 1147-1151.
42. Kuo HC, Yang KD, Juo SH, Liang CD, Chen WC, et al. (2011) ITPKC single nucleotide polymorphism associated with the Kawasaki disease in a Taiwanese population. PLoS One 6: e17370.
43. Lin MT, Wang JK, Yeh JI, Sun LC, Chen PL, et al. (2011) Clinical Implication of the C Allele of the ITPKC Gene SNP rs28493229 in Kawasaki Disease: Association With Disease Susceptibility and BCG Scar Reactivation. Pediatr Infect Dis J 30: 148-152.
44. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, et al. (2006) Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113: 2606-2612.
45. Seki M, Kobayashi T, Kobayashi T, Morikawa A, Otani T, et al. (2011) External validation of a risk score to predict intravenous immunoglobulin resistance in patients with kawasaki disease. Pediatr Infect Dis J 30: 145-147.